<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908542</url>
  </required_header>
  <id_info>
    <org_study_id>16-048</org_study_id>
    <nct_id>NCT02908542</nct_id>
  </id_info>
  <brief_title>Search for New Genetic Causes of Hypercalcemia by Massively Parallel Sequencing of a Genes Panel</brief_title>
  <acronym>HyCaGene</acronym>
  <official_title>Search for New Genetic Causes of Hypercalcemia by Massively Parallel Sequencing of a Genes Panel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypercalcemia, whether chronic or acute, exposes the patient to potentially serious&#xD;
      complications (arrhythmias, nephrolithiasis, nephrocalcinosis, ...). Prevention relies&#xD;
      primarily on effective etiological necessary for taking matched load. Under the French&#xD;
      reference center for rare disorders of calcium and phosphorus, the investigators looked for&#xD;
      mutations in the coding sequence of the CYP24A1 gene (encoding the enzyme responsible for the&#xD;
      breakdown of vitamin D), among patients with hypercalcemia without hyperparathyroidism with&#xD;
      hypersensitivity to vitamin D. However, only 25% of these patients have a genetic anomaly&#xD;
      suggesting the involvement of other genes (Molin et al. 2015). Recently our team, combined&#xD;
      with Kaufmann et al. (2014 JCEM) validated the interest of the determination of metabolites&#xD;
      of vitamin D by liquid chromatography-tandem mass spectrometry (LC-MS / MS), as biological&#xD;
      pre-screening stage for patients with hypercalcemia.&#xD;
&#xD;
      The objective of this project is to complement the molecular and biochemical studies of&#xD;
      patients without mutation of the coding sequence of CYP24A1, in a gene candidate approach&#xD;
      using massively parallel sequencing (MPS) which allows to study a panel of gene potentially&#xD;
      involved in disorder of metabolism of calcium and phosphorus. Highlighted variations will be&#xD;
      tested in silico, and if possible in vitro. The investigators will also use LC-MS / MS to&#xD;
      evaluate in vivo the effects of these variations on the metabolism of vitamin D, to develop a&#xD;
      genotype / phenotype correlation.&#xD;
&#xD;
      The work carried out within the Genetics Department Caen University Hospital in collaboration&#xD;
      with physicians of the rare disease reference center of the metabolism of calcium and&#xD;
      phosphorus should identify new genetic mechanisms underlying hypercalcemia. At the time of&#xD;
      development of personalized medicine, it will adapt the therapy in patients at risk for&#xD;
      metabolic complications and / or kidney following administration of vitamin D and finally to&#xD;
      offer genetic counseling.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of identified genetic variations presumed pathogenic</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">185</enrollment>
  <condition>Hypercalcemia</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>genetic analysis with massively parallel sequencing</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood or DNA samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with medical history of hypercalcemia without hyperparathyroidism&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Chronic hypercalcemia or at least one episode of acute hypercalcemia not linked to&#xD;
             hyperparathyroidism&#xD;
&#xD;
          -  Consent to the realization of a genetic analysis for medical purposes Non-inclusion&#xD;
             criteria&#xD;
&#xD;
          -  Another genetic disorder identified with hypercalcemia (eg Williams-Beuren syndrome)&#xD;
&#xD;
          -  Primary hyperparathyroidism (high PTH)&#xD;
&#xD;
          -  neoplasia&#xD;
&#xD;
          -  granulomatosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Caen Hospital University</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 5, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercalcemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be communicated to the referent physician of the patient.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

